J&J settles Risperdal male breast growth lawsuit on first day of trial


On the first day of a trial involving a man who claims taking the antipsychotic drug Risperdal caused him to suffer from embarrassing breast growth, the company behind the drug reached settlement terms with the Plaintiff.

According to a Bloomberg report, Johnson & Johnson and Aron Banks reached a confidential settlement on the first day of a scheduled trial. Banks was out to prove that taking Risperdal for four years as a child resulted in him developing breast growth.  Lawyers representing Banks said that the company profited billions of dollars while also collecting a “human cost” by marring the childhoods of those affected by this side effect.

The report indicates that at least 420 personal injury lawsuits have been filed against Johnson & Johnson resulting from Risperdal side effects. Among those are 120 lawsuits filed by young men who say they developed growth in their breast tissue while taking the drug.

Also in Banks’ Risperdal complaint is the fact that he was prescribed the drug as a child from 2000 through 2004 even though it has not been approved for use in treating chidren.

Legal issues are not unfamiliar for Johnson & Johnson, especially over problems stemming from Risperdal. Most recently, the company agreed to a $2.2 billion fine with the U.S. Dept. of Justice to settle and close an investigation that the company illegally marketed Risperdal for off-label purposes without any data to back claims that it was safe or effective.